NC 111585Alternative Names: NNC 111585
Latest Information Update: 24 Jun 2003
At a glance
- Originator Novo Nordisk
- Mechanism of Action Muscarinic M1 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 06 Dec 2000 New profile
- 06 Dec 2000 Preclinical development for Alzheimer's disease in Denmark (Unknown route)